These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 18516315)

  • 1. Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.
    Townsend ML; Pound MW; Drew RH
    Ther Clin Risk Manag; 2007 Dec; 3(6):1059-70. PubMed ID: 18516315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tigecycline: a new glycylcycline antimicrobial.
    Townsend ML; Pound MW; Drew RH
    Int J Clin Pract; 2006 Dec; 60(12):1662-72. PubMed ID: 17109673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tigecycline: a glycylcycline antimicrobial agent.
    Doan TL; Fung HB; Mehta D; Riska PF
    Clin Ther; 2006 Aug; 28(8):1079-1106. PubMed ID: 16982286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline.
    Reygaert WC
    Ther Clin Risk Manag; 2010 Sep; 6():419-30. PubMed ID: 20856688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
    Bradford PA; Weaver-Sands DT; Petersen PJ
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S315-32. PubMed ID: 16080070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tigecycline.
    Bhattacharya M; Parakh A; Narang M
    J Postgrad Med; 2009; 55(1):65-8. PubMed ID: 19242083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012.
    Renteria MI; Biedenbach DJ; Bouchillon SK; Hoban DJ; Raghubir N; Sajben P; Mokaddas E
    Diagn Microbiol Infect Dis; 2014 May; 79(1):54-9. PubMed ID: 24582580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tigecycline: a critical analysis.
    Stein GE; Craig WA
    Clin Infect Dis; 2006 Aug; 43(4):518-24. PubMed ID: 16838243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic.
    Jones CH; Petersen PJ
    Drugs Today (Barc); 2005 Oct; 41(10):637-59. PubMed ID: 16389407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The glycylcyclines: a comparative review with the tetracyclines.
    Zhanel GG; Homenuik K; Nichol K; Noreddin A; Vercaigne L; Embil J; Gin A; Karlowsky JA; Hoban DJ
    Drugs; 2004; 64(1):63-88. PubMed ID: 14723559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.
    Meagher AK; Ambrose PG; Grasela TH; Ellis-Grosse EJ
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):165-71. PubMed ID: 16105560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tigecycline for the treatment of infections due to resistant Gram-positive organisms.
    Squires RA; Postier RG
    Expert Opin Investig Drugs; 2006 Feb; 15(2):155-62. PubMed ID: 16433594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antibiotic agents: problems and prospects.
    Weber DJ; Rutala WA
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-97-107. PubMed ID: 23577500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tigecycline: a critical update.
    Shakil S; Akram M; Khan AU
    J Chemother; 2008 Aug; 20(4):411-9. PubMed ID: 18676218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.
    Grolman DC
    Int J Infect Dis; 2007 May; 11 Suppl 1():S7-15. PubMed ID: 17603950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.